Printer Friendly

ROPAK LABORATORIES REPORTS RESULTS

 ROPAK LABORATORIES REPORTS RESULTS
 IRVINE, Calif., March 6 /PRNewswire/ -- Ropak Laboratories


(NASDAQ: RPKL) today announced results of operations for its first quarter ended Dec. 31, 1991. Sales for the first quarter were $264,136, resulting in a net loss of $861,295, or $.17 per share.
 The company noted that revenues in the quarter ended Dec. 31, 1991, continued a downward trend experienced in the second half of 1991. This trend was recently reversed in January and February 1992, in which sales were $121,000 and $140,000, respectively. Management attributes recent sales improvement to the reorganization of its sales and marketing staff and implementation of new programs after having terminated an exclusive distributor agreement in late 1991. The company anticipates that reacquisition of control over its channels of distribution and the reorganization and expansion of sales and marketing will reflect continued revenue growth and improved results during 1992.
 Ropak Laboratories develops and produces proprietary tests to evaluate potential toxicity to humans posed by a wide variety of chemicals and compounds used in household, consumer and industrial products. The company's methods provide a cost-effective, rapid and consistent in vitro alternative to live animal testing. Tests currently offered to assess product safety include Eytex for ocular irritation, Skintex for dermal toxicity, and a recently introduced Solatex test to determine potential for photoirritancy.
 ROPAK LABORATORIES
 (Unaudited)
 Three months ended Dec. 31 1991 1990
 Revenues $ 264,136 $ 298,525
 Costs and expenses from operations 1,251,511 273,569
 Other expense (income) (126,080) 9,000
 Net income (loss) $ (861,295) $ 15,956
 Income (loss) per common share $(.17) $.01
 Weighted average shares outstanding 5,123,619 2,635,457
 -0- 3/6/92
 /CONTACT: William M. Curtis of Ropak Laboratories, 714-752-6611; or Fran Daniels of Financial Sciences of America, 310-278-4413, for Ropak/
 (RPKL) CO: Ropak Laboratories ST: California IN: SU: ERN


GK-OT -- NY005 -- 5749 03/06/92 09:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 6, 1992
Words:318
Previous Article:FITCH ISSUES NEW V-RATINGS ON $12.1 BILLION CMOs -- FITCH FINANCIAL WIRE --
Next Article:STATE OF THE ART INC. TO HIRE 93 NEW EMPLOYEES
Topics:


Related Articles
WILLIAM J. FISHER NAMED PRESIDENT AND COO OF ROPAK LABORATORIES
ROPAK LABORATORIES ANNOUNCES REPURCHASE AGREEMENT FOR MARKETING RIGHTS SIGNED
ROPAK LABORATORIES DISTRIBUTION AGREEMENT SIGNED WITH TECNOTESTS IN BRAZIL
U.S. COURT OF APPEALS UPHOLDS INJUNCTION AGAINST ROPAK IN PERSTORP XYTEC PATENT INFRINGEMENT LAWSUIT
PRELIMINARY INJUNCTION AGAINST ROPAK TAKES EFFECT; PERSTORP XYTEC PURSUES ITS PATENT INFRINGEMENT LAWSUIT
ROPAK LABORATORIES REPORTS FISCAL YEAR RESULTS OF SEVEN MONTHS ENDED SEPT. 30, 1991
ROPAK LABORATORIES SIGNS AGREEMENT WITH WORLD'S EIGHTH-LARGEST CHEMICAL AND PHARMACEUTICAL COMPANY
PERSTORP XYTEC AND ROPAK CORPORATION REACH AGREEMENT IN PATENT SUIT
/C O R R E C T I O N -- PERSTORP XYTEC/
VitroTech's Revolutionary Performance Additive Vitrolite(R) Adopted by Plastics Industry Leader Ropak Packaging.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters